MedPath

Bone Health Observational Study

Completed
Conditions
Prostate Cancer
Registration Number
NCT00632905
Lead Sponsor
CMX Research
Brief Summary

Prostate Cancer patients treated with LHRH agonists (e.g., goserelin) lose Bone Mineral Density (BMD). Using a prospective, observational study design, we propose that monitoring how physicians manage Cancer Treatment Induced Bone Loss(CTIBL) in their patients. The gold standard for evaluating BMD is dual energy x-ray absorptiometry (DEXA). The proposed study will provide some of the first prospective data on the rates of Skeletal Related Events (SREs) in prostate cancer patients undergoing ADT and help develop official guidelines on the use of DEXA screening for prostate cancer patients.

Detailed Description

A consequence of ADT is the gradual bone loss, so-called cancer treatment induced bone loss (CTIBL). The current standard of care is the addition of Vitamin D and Calcium upon the initiation of ADT. Moreover, bisphosphonates are now being considered to treat and prevent CTIBL. However, bisphosphonates are costly, thus there is a desire to identify or target a specific subset of patients who would most benefit from the treatment.

By obtaining baseline BMD and monitoring for Skeletal Related Events (SREs), we hope to identify that specific sub-set of patients who would most benefit from the treatment. Using a prospective, observational study design, we propose monitoring how physicians manage CTIBL in their patients.

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
599
Inclusion Criteria
  • Patients willing to provide written Informed Consent.
  • Patients for whom Androgen Deprivation Therapy (ADT) with Zoladex® is indicated for at least 1 year.
  • Patients started on Zoladex® within the last 4 months.
Exclusion Criteria
  • Patient had surgery or significant traumatic injury occurring within 1 month prior to consent.
  • Known hypersensitivity to Goserelin Acetate or any of the components found in Zoladex®.
  • Any concurrent condition that would make it undesirable, in the physician's opinion, for the subject to participate in the study or would jeopardize compliance with the protocol.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Bone Mineral Density of the lumbar spine12 months
Secondary Outcome Measures
NameTimeMethod
Overall Safety12 Months

Trial Locations

Locations (40)

Mor Urology Inc

🇨🇦

Newmarket, Ontario, Canada

Urotec

🇨🇦

Oshawa, Ontario, Canada

Dr. Jonathan L. Giddens

🇨🇦

Brampton, Ontario, Canada

Brantford Urology Research Medical Arts Bldg.

🇨🇦

Brantford, Ontario, Canada

Dr. Richard Sowery

🇨🇦

Burlington, Ontario, Canada

Guelph Urology Associates

🇨🇦

Guelph, Ontario, Canada

Dr. Alvaro Morales

🇨🇦

Kingston, Ontario, Canada

GU Trials Markham

🇨🇦

Markham, Ontario, Canada

Medical & Dental Bldg

🇨🇦

North Bay, Ontario, Canada

Stanley Flax Medicine Professional Corporation

🇨🇦

North York, Ontario, Canada

York-Finch Med Centre

🇨🇦

North York, Ontario, Canada

The Fe/Male Health Centres

🇨🇦

Oakville, Ontario, Canada

Orillia Urology Associates

🇨🇦

Orillia, Ontario, Canada

Mahoney Medicine Professional Corporation

🇨🇦

Ottawa, Ontario, Canada

2150935 Ontario Inc

🇨🇦

Owen Sound, Ontario, Canada

Kawartha Urology Associates

🇨🇦

Peterborough, Ontario, Canada

Dr. Allan Abramovitch

🇨🇦

Scarborough, Ontario, Canada

Dr. Peter Roney

🇨🇦

Smiths Falls, Ontario, Canada

The Medical Centre

🇨🇦

Peterborough, Ontario, Canada

West Arthur Place

🇨🇦

Thunder Bay, Ontario, Canada

Northern Urology Centre

🇨🇦

Sudbury, Ontario, Canada

Dr. Edward Woods

🇨🇦

Toronto, Ontario, Canada

The Male Health Centre

🇨🇦

Toronto, Ontario, Canada

ABHM Associates

🇨🇦

Windsor, Ontario, Canada

Dr. Louis-Rene Barrette

🇨🇦

Chicoutimi, Quebec, Canada

Dr. Roger Buckley

🇨🇦

Willowdale, Ontario, Canada

Centre de Récherche en Urologie de Lanaudiére

🇨🇦

St. Charles-Baromee, Quebec, Canada

Medical Arts Bldg

🇨🇦

Saskatoon, Saskatchewan, Canada

G. Kenneth Jansz Medicine Professional Corporation

🇨🇦

Burlington, Ontario, Canada

Southern Interior Medical Research Corporation

🇨🇦

Kelowna, British Columbia, Canada

Recherches Cliniques Theradev

🇨🇦

Granby, Quebec, Canada

Bruce W. Palmer Urology Inc.

🇨🇦

Kentville, Nova Scotia, Canada

Westmount Med Bldg

🇨🇦

Westmount, Quebec, Canada

Polyclinique Med Concorde

🇨🇦

Laval, Quebec, Canada

Ultra-Med Inc.

🇨🇦

Point Claire, Quebec, Canada

Dr. John A. Warner

🇨🇦

Burnaby, British Columbia, Canada

Central Island Research Centre

🇨🇦

Port Alberni, British Columbia, Canada

Andreou Research

🇨🇦

Surrey, British Columbia, Canada

Clinique d'Urologie du Saguenay

🇨🇦

Saguenay, Quebec, Canada

Nanaimo Urology Associates

🇨🇦

Nanaimo, British Columbia, Canada

© Copyright 2025. All Rights Reserved by MedPath